Aravive, Inc. (NASDAQ: ARAV) Files An 8-K Other EventsItem 8.01 Other Events.
On December 11, 2018, Aravive, Inc. (the “Company”) issued a press release announcing that the Company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer.
The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01Financial Statements and Exhibits.
The following exhibit is filed with this Current Report on Form 8-K:
Aravive, Inc. ExhibitEX-99.1 2 vsar-ex991_6.htm EX-99.1 vsar-ex991_6.htm EX 99.1 Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer HOUSTON,…To view the full exhibit click